REGN vs THRY · P/E 14, rev $14.34B vs P/E 11, rev $824.2M
Regeneron Pharmaceuticals Inc (REGN) versus Thryv Holdings Inc (THRY) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Thryv Holdings Inc (THRY) is a software - application company listed on NASDAQ.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Latest reported THRY revenue for 2024-12-31 was $824.2M. Net income was -$74.2M. Revenue was down 10.1% from 2023-12-31 to 2024-12-31. THRY currently screens at market cap $156.6M and trailing P/E 10.7.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. THRY currently screens at market cap $156.6M and trailing P/E 10.7.
Not investment advice. Open the REGN and THRY stock pages for the full models.
Not investment advice.